BALCAO · PHARMACEUTICAL PREPARATIONS
Bespoke Extracts, Inc. BSPK
14 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.1M
▲ 42.3% vs FY2023
EPS · FY24
$-0.10
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-92.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.1M
Revenue, FY2024 · full 14-year series below
Revenue
Net income
The company lost 93 cents on every revenue dollar this year.
Per share
USD -0.10
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-89.0%
Net margin-92.8%
Return on assets-290.8%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+78.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+215.5%
+78.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 359,088.00
total assets, end of FY2024
Total assetsUSD 359,088.00
EquityUSD -2.1M
CashUSD 60,305.00
Gross debtUSD 310,000.00
Net debtUSD 249,695.00
Current ratio0.15×
Net debt stands at -12% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
·
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.10
−0.15
−0.44
−0.19
−0.04
0.04
−0.21
−0.48
−0.13
−0.30
−0.25
−0.09
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−624.7
−130.8
·
·
·
·
−531.3
−142.9
−54.8
−45.8
−94.5
−248.7
Shares out B
0.01
0.01
0.01
0.01
0.19
0.08
0.04
0.03
0.00
0.00
0.00
0.01
0.33
0.34
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed